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Cognitive, creative, functional, and clinical symptom
improvements in schizophrenia after an integrative cognitive
remediation program: a randomized controlled trial
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This study analyzed the effectiveness of an integrative cognitive remediation program (REHACOP) in improving neurocognition,
social cognition, creativity, functional outcome, and clinical symptoms in patients with schizophrenia. In addition, possible
mediators predicting improvement in functional outcomes were explored. The program combined cognitive remediation with
social cognitive training and social and functional skill training over 20 weeks. The sample included 94 patients, 47 in the REHACOP
group and 47 in the active control group (occupational activities). Significant differences were found between the two groups in
change scores of processing speed, working memory, verbal memory (VM), inhibition, theory of mind, emotion processing (EP),
figural creative strengths, functional competence, disorganization, excitement, and primary negative symptoms. A mediational
analysis revealed that changes in VM, inhibition, and EP partially explained the effect of cognitive remediation on functional
competence improvement. This study provides initial evidence of the effect of integrative cognitive remediation on primary
negative symptoms and creativity.
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INTRODUCTION
Schizophrenia is considered to be one of the most disabling
diseases in the world1. People who suffer from it have a high level
of dependency in multiple functional domains at very early
ages2,3, and this functional disability has a major impact on the
quality of life of both patients and caregivers or relatives4. In spite
of the advances in pharmacological treatment, this has not shown
to be effective at improving functional outcome5. Therefore,
functional impairment remains the most significant and challen-
ging treatment target in this disorder.
In an attempt to develop interventions that improve functional
disability, many studies have focused on hindering factors6–9.
Studies have indicated that deficits in neurocognition and social
cognition, as well as clinical symptoms, are the most important
factors in predicting functional outcome10–16. In addition, it has
been suggested that other positive personal resources such as
creative capacity may have an influence on the functional
outcome of people with this disease9,17,18. All these findings
suggest that interventions aimed at improving these factors could
improve functional outcomes. In the last two decades, various
meta-analyses have concluded that cognitive remediation is
effective in improving not only neurocognition and social
cognition, but also clinical symptoms and functional outcomes
of people with schizophrenia19–23.
It has also been shown that combining different kinds of
interventions results in greater improvements than the imple-
mentation of cognitive remediation alone24. For instance, some
studies have combined cognitive remediation with social cogni-
tive training25–31 and others have employed a combination of
cognitive remediation with social skill training32, with functional
skill training33, or with both social and functional skill training34,35.
There is also evidence of improvement after cognitive remediation
combining cognitive training, social cognitive training, and social
and functional skill training36. However, the benefits of combining
different training forms have only been reported by a hetero-
geneous and small number of studies. Moreover, some of these
studies have suggested that future research should improve
several methodological issues that have been raised25–27,32,36,
including the kind of measures used for the assessment of social
cognition, functional outcome, and negative symptoms, as well as
the inclusion of an active control group. In addition, owing to the
heterogeneity of intervention types, there is no consensus as to
how to combine different trainings. Considering that patients with
schizophrenia show impairment in numerous domains (e.g.,
neurocognition, social cognition, social skills, and functional
outcome), we expect that combining training in all of these
domains would be more effective than, for example, combining
only neurocognition and social cognition or neurocognition and
social skills training. Furthermore, it is possible that interventions
that include social skills training may have an especially beneficial
effect on negative symptoms, such as asociality, apathy, or
anhedonia37.
Another relevant factor that seems to influence functional
outcomes among patients with schizophrenia is creativity9,17.
Several studies have shown that the creative performance of
patients with schizophrenia is partly explained by multiple
neurocognitive and social cognitive domains38–41. In other words,
patients with a better capacity in neurocognition and social
cognition (e.g., executive functions, processing speed (PS), or
theory of mind (ToM) seem to evidence better creative
performance. This suggests that patients who improve cognitive
functioning could also improve creative capacity, and so if
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cognitive remediation improves cognition, it is also possible that
this improvement may indirectly improve creative ability in this
disease. As far as the authors are aware, only one study42 to date
has analyzed whether cognitive remediation could improve
creativity in people with schizophrenia, although as this study
lacked a patient control group, more research is needed.
Despite the effectiveness of cognitive remediation in improving
functional outcomes, still little is known about the mechanisms
through which cognitive remediation proves effective43. This is
important both for the development of more personalized treatment
plans44 and for the proper use of healthcare resources24. Specifically,
research on the cognitive changes associated with functional
improvement has tended to be scarce and specific associations are
still uncertain43. Some of the cognitive domains where changes have
been associated with improved functional outcomes include
executive functioning45,46, working memory (WM)47, verbal memory
(VM)15,48, PS15,47, and emotional management46. Few studies have
explored the cognitive changes related to functional improvement
after cognitive remediation combined with other trainings15,35,46. For
instance, in the study by Eack et al.46, improvement in VM, executive
functions, and emotional management mediated the relationship
between receiving cognitive remediation and functional outcome
improvement. In another study15, change in VM and PS mediated
between receiving cognitive remediation and improvement in
functional outcome. Moreover, taking into account the results of
other cross-sectional studies that have analyzed predictors of
functional outcome9–13, it would be expected that improvement in
other neurocognitive and social cognitive domains, as well as in
clinical symptomatology—mainly negative symptoms— could pre-
dict improvement in functional outcome. For example, in the study
by Sánchez et al.35, improvement in negative symptoms was
associated with improvement in functional outcome after cognitive
remediation, although no mediation hypothesis was tested.
Taken together, although cognitive remediation has been
shown to improve multiple domains in schizophrenia, few studies
have encompassed a combination of training in neurocognition,
social cognition, social and functional skills. Moreover, some of
these studies have reported limitations in the measures employed
for social cognition and negative symptoms25,36. As far as the
authors are aware, no study to date has explored whether
integrative cognitive remediation can also improve creativity and
primary negative symptoms in people with schizophrenia
compared with an active control group.
Therefore, the main aim of this study was to analyze the
effectiveness of an integrative group-based cognitive remediation
program (REHACOP) that combines training in neurocognition,
social cognition, and social and functional skills among patients
with schizophrenia in multiple domains: neurocognition, social
cognition, creativity, functional outcome, and clinical symptoms.
An additional aim was to assess the mechanisms through which
functional outcome improves after implementing the integrative
cognitive remediation program.
RESULTS
Eighty-one patients completed the post-treatment evaluation,
resulting in an attrition rate of 13.82% (Fig. 1). Statistical analyses
were performed with the 94 randomized patients, following the
intention-to-treat (ITT) principle. In addition, per-protocol analyses
were also performed only with participants who had completed
the post-treatment assessment (Supplementary Tables 1–4). The
baseline sociodemographic and clinical characteristics of the
REHACOP group and the active control group can be found in
Table 1. No significant differences between both groups were
found in any of these variables. Statistically significant differences
were found between inpatients and outpatients in VM (F= 4.034,
p= 0.048), positive symptoms (F= 14.766, p < 0.001), primary
negative symptoms (F= 5.031, p= 0.027), disorganization
(F= 4.847, p= 0.030), and excitement (F= 4.672, p= 0.033)
change scores. Specifically, inpatients showed greater improve-
ment in clinical symptoms, whereas outpatients showed greater
improvement in VM. The hospitalization status variable was,
Fig. 1 CONSORT flow diagram of study recruitment. CONSORT= Consolidated standards of reporting trials.
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therefore, introduced as a covariate in the subsequent analyses
with these change scores. Regarding satisfaction with the
treatment received, the REHACOP group showed greater overall
satisfaction compared to the active control group (U= 772.00,
p= 0.010).
Changes in neurocognition, social cognition, and creativity
Significant differences between the REHACOP group and the
active control group at baseline were only found in verbal
creativity (U= 805.00, p= 0.023), with the REHACOP group
showing higher scores in this domain (Table 2).
Statistically significant differences in change scores between the
REHACOP group and the active control group were found in PS,
WM, VM, inhibition, ToM, EP, and figural creative strengths (Table 4),
in which the REHACOP group improved compared with the active
control group. The effect size was medium-large for all these
measures, except for figural creative strengths, with a small
effect size.
Changes in clinical symptoms and functional outcome
Significant differences between the REHACOP group and the
active control group at baseline were only found in positive
symptoms (t=−2.14, p= 0.035), with the REHACOP group
showing higher scores in baseline positive symptoms (Table 3).
Analysis of covariance showed statistically significant differences
in change scores between the REHACOP group and the active
control group in functional competence, primary negative
symptoms, disorganization, and excitement (Table 4). The effect
size was large for functional outcome, medium for primary
negative symptoms and disorganization, and small for excitement.
Mediational model explaining improvement in functional
outcome
A mediational analysis was performed on the change score of
functional competence. A model with a path analysis was
estimated which included only those mediating variables that
had had a significant correlation with the change in functional
competence: VM, inhibition, EP, and primary negative symptoms.
The independent variable was the group (REHACOP group vs
active control group). Based on previous literature49–52, the
baseline score of functional competence as well as age and IQ
were included to control their possible influence. The model had a
good fit, SB χ2 (7, N= 94)= 2.670, Comparative Fit Index (CFI)=
1.000, non-normed fit index (NNFI)= 1.000, and standard residual
mean square root (SRMR)= 0.033.
The covariance between the group and baseline score for
functional competence, the covariance between the mediating
variables, the paths from age and IQ to the mediating and
outcome variables, and the path from change score in primary
negative symptoms to the outcome variable were not statistically
significant. Therefore, in order to obtain a more parsimonious
model, a new model was estimated that included only the
significant paths, omitting those variables that were not
associated with mediators or outcome variables (age, IQ, and
change score in primary negative symptoms). The final model
obtained is shown in Fig. 2. As can be seen, group (for the
REHACOP group) was positively related to changes in VM,
inhibition, and EP, and these three mediating variables were
positively associated with change in functional competence. In
addition, the group was directly and positively associated with a
change in functional competence. Finally, baseline functional
competence was also directly and negatively associated with a
change in functional competence, indicating that a lower baseline
score was related to greater change in functional outcome after
the intervention. The model also had a good fit, SB χ2 (7, N= 94) =
4.282, CFI= 1.00, NNFI= 1.00, and SRMR= 0.052. Next, the
significance of the mediational paths was examined via 5,000
bootstrapping samples. The results revealed that change in VM
(1.260; 95% confidence interval [1.260, 1.296]), change in
inhibition (0.854; 95% confidence interval [0.838, 0.870]), and
change in EP (1.306; 95% confidence interval [1.285, 1.326]) acted
as mediating variables between group and change in functional
competence.
DISCUSSION
The first aim of this study was to analyze the effectiveness of an
integrative group-based cognitive remediation program (REHA-
COP) that combined training in neurocognition, social cognition, as
well as social and functional skills among patients with schizo-
phrenia. In line with previous studies carried out with integrative










Age (years) 40.60 10.45 41.43 10.41 0.386 0.701
Education (years) 10.32 2.38 9.87 2.89 0.818 0.416
Gender Males 41 (87.2%) 37 (78.7%) 1.205 0.272
Females 6 (12.8%) 10 (21.3%)
Handedness Right-handed 39 (80.9%) 38 (83%) 2.613 0.217
Left-handed 0 (0%) 2 (4.3%)
Mixed-handed 9 (19.1%) 6 (12.8%)
Age of onset (years) 23.92 5.81 22.83 7.36 935.50 0.200
Previous hospitalizations 5.92 6.37 8.56 7.93 865.50 0.070
Hospitalization status Outpatients 24 (51.1%) 24 (51.1%) 0.000 1.000
Inpatients 23 (48.9%) 23 (48.9%)
Medication dosage 501.85 286.64 465.75 188.60 1074.00 0.818
Premorbid IQ 95.13 10.11 93.09 9.98 936.50 0.203
SD standard deviation, t t test, U Mann–Whitney U, X2 Chi-squared, Medication dosage refers to chlorpromazine equivalent doses (mg/day).
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interventions combining training in neurocognition with social
cognition and/or social and functional skills25,27,28,31,34–36, patients
from the REHACOP group showed significantly greater improve-
ment than patients from the active control group in neurocogni-
tion, social cognition, creativity, functional outcome, and clinical
symptoms.
As expected and consistent with previous research25,27,28,31,34–36,
the REHACOP group showed improvements in numerous neuro-
cognitive and social cognitive domains. In particular, very large
effect sizes were found in PS, VM, ToM, and emotion processing
(EP). The significant results obtained in social cognition are
particularly interesting, since they reinforce the findings of previous
studies that used different types of measures25,31,36 (e.g., paper-
and-pencil tasks instead of videos). Contrary to some previous
studies, no significant results were found for cognitive flexibility
(CF)25,53,54 and social perception (SP)36,55. Nevertheless, SP has
received little attention in studies, and those that have assessed it
have done so in different ways.
Regarding creativity, although this capacity was not directly
trained in the intervention, we hypothesized that it would be
indirectly improved through enhancements in social cognition
and neurocognition38–41. In fact, some of the abilities trained in
the REHACOP included novel problem solving and CF, which is
closely related to creativity38,40. Significant differences between
groups were found only in the change scores of figural creative
strengths. Although the REHACOP group showed only a very small
improvement in figural creative strengths at post-treatment, the
active control group showed a decrease in this creativity variable.






Mean (95% CI) SD Mean (95% CI) SD t/U p
Neurocognition
CF
Pre 0.08 (−0.14–0.30) 0.74 −0.08 (−0.40–0.19) 1.02 1033.50 0.591
Post 0.15 (−0.07–0.38) 0.74 −0.17 (−0.49–0.13) 1.06
PS
Pre 0.15 (−0.12–0.39) 0.90 −0.15 (−0.35–0.06) 0.77 1.676 0.097
Post 0.32 (0.05–0.58) 0.88 −0.33 (−0.56 to −0.11) 0.76
WM
Pre 0.16 (−0.08–0.40) 0.86 −0.17 (−0.47–0.15) 1.11 899.00 0.112
Post 0.30 (0.04–0.62) 1.00 −0.34 (−0.58 to −0.08) 0.92
VM
Pre 0.02 (−0.23–0.30) 0.92 −0.02 (−0.29–0.28) 0.94 0.171 0.864
Post 0.28 (−0.01–0.58) 1.00 −0.27 (−0.49 to −0.03) 0.81
Inhibition
Pre 0.08 (−0.22–0.38) 0.98 −0.08 (−0.33–0.17) 0.87 0.817 0.416
Post 0.31 (0.04–0.59) 0. 92 −0.29 (−0.55 to −0.07) 0.86
Social cognition
ToM
Pre 4.55 (3.85–5.25) 2.40 3.70 (2.93–4.47) 2.70 892.50 0.106
Post 5.37 (4.90–5.88) 1.70 3.23 (2.71–3.79) 1.89
SP
Pre 9.34 (8.26–10.58) 4.03 8.77 (7.33–10.08) 5.03 1006.50 0.458
Post 10.61 (9.45–11.73) 3.83 10.69 (9.59–11.80) 3.96
EP
Pre 14.70 (13.50–15.84) 3.98 14.79 (13.71–15.96) 3.95 1062.50 0.750
Post 16.11 (15.22–16.91) 2.95 14.02 (12.83–15.11) 4.01
Creativity
Figural creativity
Pre 50.44 (44.55–56.33) 21.51 44.66 (39.65–50.27) 18.62 1.392 0.167
Post 51.65 (44.51–58.39) 23.30 45.99 (42.17–50.13) 14.34
Figural creative strengths
Pre 2.26 (1.67–2.96) 2.32 2.75 (1.95–3.79) 3.23 1034.50 0.591
Post 2.30 (1.59–3.13) 2.53 1.74 (1.19–2.41) 2.17
Verbal creativity
Pre 19.89 (17.02–23.42) 10.69 15.14 (13.17–17.14) 7.57 805.00 0.023
Post 20.67 (17.44–23.94) 11.11 17.05 (14.41–19.74) 8.48
CF cognitive flexibility, PS processing speed, WM working memory, VM verbal memory; ToM Theory of Mind, SP social perception, EP emotion processing,
CI confidence interval, SD standard deviation, t t test, U Mann–Whitney U. CI was derived from the bootstrap analysis.
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The fact that significant results were not found in the other
creativity domains could be partly due to the kind of occupational
activities that the active control group performed (e.g., handi-
crafts, painting, and music), which are closely related to creativity.
The lack of research makes it difficult to compare these results
with other studies. Kiritsis42 found an improvement in creativity
after cognitive remediation in patients with schizophrenia, but
their results were not compared with a patient control group.
With respect to functional outcome and in line with previous
studies carried out with integrative cognitive interventions28,34,36,
the REHACOP group showed significantly higher change scores in
functional competence, with a very large effect size. Significant
results were not found for other functional outcome measures,
which could be partly due to the smaller sample size of these
measures. In addition, the COVID-19 pandemic may have
influenced these results, as some of the social activities that were
assessed may have been undermined by lockdown measures,
which were especially restrictive when sessions with several
intervention groups were held. Other studies that have applied a
combined intervention did not find significant results in functional
outcome measured through similar dimensions, such as social
functioning and hedonic capacity29,30, and so cognitive remedia-
tion could benefit from also including direct intervention in social
functioning (pro-social activities, recreation, etc.) and hedonic
capacity.
With regard to clinical symptoms, the REHACOP group showed a
significant reduction in excitement, disorganization, and primary
negative symptoms compared to the active control group, with
small and medium effect sizes. The improvement in disorganization
and negative symptoms in the REHACOP group was in line with
some previous studies25,31,35,36, but not with others26,29,34. Never-
theless, it is worth mentioning that these previous studies did not
assess primary negative symptoms separately, but rather, primary
and secondary symptoms together. The improvement in primary
negative symptoms found in this study is an important result that
indicates that the effects of cognitive remediation can be general-
ized to other domains that are not directly trained. It may be
possible for the inclusion of training in social skills to have a
particular beneficial effect on improving these symptoms37.
However, since different cognitive remediation interventions were
not compared in this study, this idea should be considered with
caution. There is less evidence about the improvement in
excitement after cognitive remediation56. The lack of improvement
in positive symptoms was congruent with previous studies26,29,34–36.
Interestingly, several differences were found between out-
patients and inpatients in VM and several clinical symptom






Mean (95% CI) SD Mean (95% CI) SD t/U p
Functional outcome
Functional competence
Pre 63.41 (59.34–67.59) 13.38 60.89 (57.13–64.61) 12.83 0.93 0.353
Post 74.77 (72.14–77.47) 9.33 64.06 (59.65–68.16) 14.45
Social functioning
Pre 23.93 (22.71–25.19) 4.49 24.10 (23.08–25.28) 3.70 1073.00 0.809
Post 23.07 (21.66–24.43) 4.67 23.56 (22.61–24.55) 3.44
Hedonic capacity
Pre 76.36 (72.80–80.04) 14.05 78.71 (75.63–81.47) 9.55 918.00 0.154
Post 74.86 (71.05–78.28) 12.07 79.04 (75.69–82.23) 11.59
General self-efficacy
Pre 60.36 (55.08–66.01) 19.16 58.34 (54.42–62.03) 13.13 1056.50 0.713
Post 64.71 (60.57–69.38) 15.25 58.66 (54.22–63.30) 15.59
Clinical symptoms
Negative
Pre 29.57 (25.39–33.74) 13.97 33.80 (29.75–37.62) 13.76 1.148 0.142
Post 22.87 (18.67–27.29) 14.55 32.22 (27.93–36.27) 14.53
Positive
Pre 10.35 (9.16–11.59) 4.20 8.66 (7.71–9.66) 3.40 2.143 0.035
Post 8.55 (7.64–9.55) 3.40 8.18 (7.24–9.22) 3.54
Disorganization
Pre 7.68 (6.83–8.55) 3.07 7.54 (6.87–8.24) 2.46 0.236 0.814
Post 6.77 (6.02–7.60) 2.84 7.44 (6.80–8.06) 2.25
Excitement
Pre 7.62 (6.64–8.65) 3.66 7.10 (6.26–8.07) 3.20 1040.00 0.622
Post 6.37 (5.55–7.27) 2.94 6.87 (5.99–7.92) 3.36
Depression
Pre 6.50 (5.85–7.22) 2.46 6.33 (5.71–7.02) 2.30 1053.50 0.697
Post 5.81 (5.10–6.62) 2.51 6.13 (5.49–6.81) 2.32
CI confidence interval, SD standard deviation, t t test, U Mann–Whitney U. CI was derived from the bootstrap analysis.
A. Sampedro et al.
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change scores. Whereas outpatients benefited more in terms of
VM, inpatients showed a greater improvement in clinical
symptoms. These differences in change scores cannot be
attributed to the baseline scores or to the medication dosage,
since baseline significant differences between outpatients and
inpatients were only found in excitement and this was entered as
a covariate. Regarding the greater improvement in clinical
symptoms of inpatients, this may be partly attributed to the
hospital care routine that may have contributed to the stabiliza-
tion of symptoms (e.g., defined schedules for daily activities,








Mean change score (95% CI) SE Mean change score (95% CI) SE F p η2p
Neurocognition
CF 0.10 (−0.11–0.31) 0.10 −0.10 (−0.31–0.10) 0.31 2.10 0.153 0.022
PS 0.20 (0.08–0.33) 0.06 −0.20 (−0.33 to −0.09) 0.06 21.24 0.001 0.190
WM 0.23 (0.01–0.49) 0.12 −0.23 (−0.54–0.04) 0.15 7.27 0.014 0.074
VM 0.27 (0.06–0.48) 0.10 −0.27 (−0.43 to −0.11) 0.08 17.97 0.001 0.166
Inhibition 0.24 (0.03–0.47) 0.11 −0.24 (−0.51 to −0.01) 0.12 9.57 0.006 0.100
Social cognition
ToM 1.02 (0.45–1.53) 0.27 −0.71 (−1.16 to −0.26) 0.23 37.66 0.001 0.293
SP 1.43 (0.27–2.63) 0.60 1.75 (0.68–2.78) 0.54 0.22 0.618 0.002
EP 1.32 (0.63–2.04) 0.36 −0.73 (−1.64–0.11) 0.44 14.48 0.001 0.137
Creativity
Figural creativity 1.61 (−3.05–6.68) 2.55 −0.05 (−4.10–4.20) 2.10 0.266 0.586 0.003
Figural creative strengths −0.14 (−0.71–0.45) 0.30 −0.91 (−1.42 to −0.36) 0.26 4.45 0.034 0.050
Verbal creativity 2.53 (−0.65–5.65) 1.61 −0.04 (−3.05–2.86) 1.55 1.57 0.201 0.020
Functional outcome
Functional competence 11.72 (9.46–13.96) 1.14 2.86 (0.49–5.19) 1.17 30.85 0.001 0.253
Social functioning −0.99 (−2.05–0.08) 0.56 −0.55 (−1.33–0.21) 0.40 0.45 0.511 0.005
Hedonic capacity −2.10 (−4.74–0.34) 1.29 0.63 (−1.63–2.89) 1.11 2.66 0.123 0.028
General self-efficacy 5.12 (0.41–9.95) 2.42 −0.79 (−7.22–4.97) 3.13 3.25 0.075 0.036
Clinical symptoms
Negative −6.83 (−9.18 to −4.58) 1.24 −1.60 (−3.60–0.12) 0.93 10.95 0.003 0.108
Positive −1.56 (−2.29 to −0.80) 0.38 −0.79 (−1.56 to −0.08) 0.38 2.606 0.110 0.028
Disorganization −0.97 (−1.48 to −0.49) 0.24 −0.13 (−0.47–0.25) 0.18 8.513 0.007 0.086
Excitement −1.20 (−1.74 to −0.65) 0.27 −0.24 (−0.98–0.49) 0.38 4.606 0.041 0.049
Depression −0.71 (−1.32–0.04) 0.34 −0.20 (−0.77–0.37) 0.29 1.584 0.227 0.017
CF cognitive flexibility, PS processing speed, WM working memory, VM verbal memory, ToM Theory of Mind; SP social perception, EP emotion processing,
CI confidence interval, SE standard error, ANCOVA analysis of covariance, η2p partial eta squared, Change scores post-treatment score−pre-treatment score.
Means for change scores are adjusted for the effect of the baseline score. CI and SE for change scores were derived from the bootstrap analysis. Significance
levels were determined using F tests based on the bootstrap SE estimate for that comparison, rather than using a pooled SE estimate.
Fig. 2 Model of mediation explaining improvement in functional competence after the integrative cognitive remediation through
changes in VM, inhibition, and EP. Given values are non-standardized coefficients with standard errors in parentheses. *p ≤ 0.05, **p ≤ 0.001.
A. Sampedro et al.
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healthier lifestyle habits, personal care, etc.)57, in contrast to some
outpatients that may have a more disorganized daily routine. The
greater improvement found in outpatients in VM is in contrast
with results from Cella et al.22, a meta-analysis in which it is
suggested that the inpatient may gain greater benefit in cognition
compared with community samples. Nevertheless, the sample size
of this study does not allow us to draw conclusions as to the
influence of hospitalization status.
The second objective of this study was to explore the mediating
mechanisms through which integrative cognitive remediation
improved functional outcomes. In this study, changes in VM,
inhibition, and EP partially mediated the association between
receiving the intervention and improvement in functional
competence. In addition, lower baseline functional competence
scores were related to a greater change in this domain. The
finding that the group variable in the mediational model
continued to have a direct association with change in functional
competence was expected since the REHACOP group included
training in functional skills. The few studies that have assessed the
association between baseline functioning and functional improve-
ment after cognitive remediation in schizophrenia33,51,52,58,59 have
multiple methodological differences (e.g., measurement of func-
tional outcome or type of intervention), which does not allow
suitable comparison of results. For instance, among those studies
in which a performance-based measure of functional competence
was used (e.g., UPSA), Twamley et al.52 found lower baseline
functional competence to be related to greater changes in
functional competence. However, this study included patients
with other disorders in addition to schizophrenia, such as
schizoaffective disorder, and the intervention involved compen-
satory cognitive training rather than a drill and practice cognitive
remediation. In contrast, Kurtz51 found that higher baseline
functional competence was related to greater functional compe-
tence at post-treatment assessment, although this study also
included both patients with schizophrenia and schizoaffective
disorder who had engaged in computerized cognitive remedia-
tion or computer-skills training. Given the great disparity found
among these studies, more research is needed44.
Regarding the predicting role of cognitive changes, previous
studies have also found changes in VM15,46,48 and executive
functions45,46 to predict change in functional outcome. Similar to
EP, Eack et al.46 found improvement in emotion management to
influence change in functional outcome. Interestingly, in the study
by Eack et al.46, changes in VM, executive functions, and emotional
management were also the only domains that predicted change
in functional outcome. In the present study, change scores in
primary negative symptoms did not mediate improvement in
functional competence, which was in line with the limited
literature available15. In contrast, in the study by Sánchez
et al.35, improvement in negative symptoms was associated with
improvement in functional outcome after cognitive remediation,
although no mediation hypothesis was tested. As a whole, these
results suggest that cognitive remediation should emphasize
training in VM, executive functions, and EP. Nevertheless, findings
of this topic are heterogeneous among studies and therefore,
more research is needed before conclusions can be drawn. For
instance, in the study by Peña et al.15, executive functions, which
were assessed using the same measure as in this study, failed to
explain the functional improvement. Nor did EP, although this was
measured using a different instrument15.
Several limitations should be considered in this study. First, the
sample size may have limited the significance of some results,
especially for some functional outcome measures which included
a smaller sample size, and therefore, more data had to be
imputed. Second, the sample was skewed towards men, although
there were no sex differences between both groups. Third, the
COVID-19 pandemic caused several patients to drop out and some
intervention sessions had to be temporarily suspended, although
they were successfully resumed at a later stage. Fourth, the power
analysis was only conducted for neurocognitive domains and thus,
the rest of the domains should be considered as exploratory
outcomes. Fifth, patients were not blind to the treatment
condition received, although they were instructed not to mention
what type of treatment they would receive or had received during
evaluations, to ensure masking of the evaluators. The fact that
patients from the active control group were aware of being in the
control condition may have influenced the results. Therefore,
future studies should try to ensure all participants remain blind to
the treatment condition. However, it is worth mentioning that this
study ensured that the active group received as much social
interaction as the REHACOP group.
Bearing these limitations in mind, these findings support
previous evidence of the effectiveness of integrative cognitive
remediation in improving multiple domains, while overcoming
some methodological issues raised in previous studies25–27,32,36.
Moreover, the study provides preliminary relevant evidence of the
—somewhat slight effectiveness—of integrative cognitive reme-
diation in a creative capacity. In addition, this study shows that
integrative cognitive remediation is effective at improving primary
negative symptoms. All these results have relevant implications
for the design of treatment plans for patients with schizophrenia.
A major implication is that these findings provide strong evidence
to suggest that integrative cognitive remediation combining
training in neurocognition, social cognition, and social and
functional skills should be included as a key intervention in the
treatment plans for patients with schizophrenia, as this interven-
tion is even capable of ameliorating the primary negative
symptoms that are so resistant to pharmacological treatment. A
second implication is linked to the future lines of research that
these results open up. Considering that creativity is a key factor in
the functional outcome of these patients9 and that cognitive
remediation has been shown to produce a slight beneficial effect
on it, a second step would be to study whether including training
in creativity in combination with this integrative cognitive
intervention could improve creativity, and in turn increase benefits
in terms of functional outcome. Furthermore, it would be
interesting for future studies to analyze whether creativity is a
valued outcome in patients with schizophrenia. Moreover, future
studies could start including training not only in creativity but also
in other positive personal resources, such as humor60 or
resilience12, within integrative cognitive remediation, to see
whether these abilities produce greater benefits. In fact, the
inclusion of training in these positive resources could increase
motivation and adherence to treatment. Another implication is
that findings from this study, in line with those of Eack et al.46,
suggest that cognitive remediation should reinforce training in
VM, executive functions, and EP with a view to obtaining a greater
benefit in terms of functional competence. This reinforces the idea
that interventions benefit from combining training in both
neurocognition and social cognition. Finally, future studies might
benefit from separately analyzing the effect of cognitive remedia-
tion in outpatients and inpatients in order to gain a more-detailed
understanding of the type of patients who benefit most.
METHODS
Participants
The sample consisted of 94 patients diagnosed with schizophrenia who
were recruited from the Psychiatric Hospital of Álava and the Mental
Health Network in Álava (Spain). All patients had been diagnosed with
schizophrenia according to the Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-5)61. In addition, all patients showed
cognitive impairment. The exclusion criteria were as follows: (a) clinical
instability according to the criteria of Csernansky et al.62; (b) relevant
modifications in the antipsychotic treatment in the previous 3 months due
to an increase in the severity of clinical symptoms; (c) cognitive
A. Sampedro et al.
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impairment caused by another disease; (d) diagnosis of an active major
affective disorder; (e) being in another specific cognitive remediation
program; and (f) Substance Use Disorder (DSM-5)61 within the 3 months
before screening. The sample included both outpatients and inpatients.
The inpatient study sample consisted of patients hospitalized at a
psychiatric rehabilitation unit at the Psychiatric Hospital of Álava who
were anticipating imminent hospital discharge to the community setting.
Procedure
The sample size was determined through an a priori power analysis, based
on a previous study on REHACOP36, which used the G*Power 3 software63.
In order to obtain an effect size of d= 0.77 to see group differences in
neurocognition, with 90% power and a 5% level of significance, a sample
size of 76 subjects, 38 in each group, was deemed adequate. The rest of
the outcome measures were considered to be exploratory.
The study design was a parallel-group randomized trial, forming part of
a larger project that has been later expanded to include an additional arm
(a group receiving intense physical exercise). The cognitive remediation
arm has been completed, while the physical exercise arm is ongoing.
Therefore, in the present study, only the cognitive remediation group and
the active control group were included. The participants were randomly
assigned to each group (Fig. 1), this being done via an online computer-
generated randomization system (http://www.randomization.org). Rando-
mization was performed by a Study Coordinator who was not involved in
the assessment, study interventions, or statistical analyses. All participants
underwent a neuropsychological and psychiatric assessment at pre-
treatment and at a 5-month follow-up, with post-treatment evaluation
being conducted within the first three weeks following the end of the
intervention. All raters were blind to the experimental treatment condition
and had no other role in the study (they had no clinical responsibility for
the participants during the completion of the study and were not involved
in administering the cognitive remediation or occupational activities) that
could undermine the trial blinding. Moreover, participants were instructed
not to mention what type of treatment they would receive or had received
during evaluations.
The study protocol received the approval of the Clinical Research Ethics
Committees of the Autonomous Region of the Basque Country in Spain
(PI2017044), and the project is registered with clinicaltrials.gov
(NCT03509597). All patients participated voluntarily, providing written
informed consent to take part, and did not receive any monetary reward
for participating in the project.
Measures
The evaluation of neurocognition included measurement of the following
domains: CF, PS, WM, VM, and inhibition. All the scores were converted
into Z scores based on the study sample and some scores were adjusted to
make higher scores indicate better cognitive performance. A composite
score was calculated using the number of categories completed and the
number of perseverative errors obtained using the Modified Wisconsin
Card Sorting Test64 for assessment of CF (Cronbach’s alpha= 0.74). PS was
measured by the Symbol-Coding from the Wechsler Adult Intelligence
Scale-III (WAIS-III)65 and the Stroop Color and Word Test (SCWT)66 (Word
and Color scores) (Cronbach’s alpha= 0.80). The Backward Digit Span from
the WAIS-III65 was used for assessment of WM, whereas VM was measured
using a composite score obtained from the three learning trials and the
delayed recall trial in accordance with the Hopkins Verbal Learning Test
Revised (version 2 at baseline and 4 at post treatment)67 (Cronbach’s alpha
= 0.84). Finally, the SCWT66 (Word-Color and Interference scores) was used
for inhibition (Cronbach’s alpha= 0.84).
Social cognition was measured through ToM, SP, and EP. The Happé Test
“Strange Stories Task”68 was used for the assessment of ToM (four different
stories at baseline and follow-up). SP was measured through the Social
Attribution Task-Multiple Choice (version 2 at baseline and 1 at post-
treatment)69, a video of a social drama enacted by geometric figures. EP
was evaluated through the Spanish adaptation of the Bell Lysaker Emotion
Recognition Test (version 2 at baseline and 1 at post-treatment)70, a video
showing an actor portraying different effects.
Creativity was evaluated using two subtests from the Torrance Test of
Creative Thinking71,72 (version A at baseline and version B at post-
treatment). Figural creativity was assessed with the Picture Completion
subtest. The total figural creativity score was calculated by adding scores
for originality, elaboration, fluency, resistance to premature closure, the
abstractness of titles, and flexibility. In addition, a figural creative strengths
score was obtained according to the manual72. The Unusual Uses subtest
was used for the assessment of verbal creativity. Total verbal creativity
score was calculated by adding scores for the originality, fluency, and
flexibility dimensions. A more-detailed explanation of these tests has been
provided elsewhere39.
The assessment of functional outcome included the following tests.
Functional competence was measured by the Spanish Version of the
University of California, San Diego, Performance-Based Skills Assessment73,
assessing the performance of everyday activities in different areas. Social
functioning was evaluated by means of the short Spanish version of the
Social Functioning Scale74, whereas the Spanish adaptation of the
Anticipatory and Consummatory Interpersonal Pleasure Scale-Adult
version75 was used to assess hedonic capacity for social interactions.
General self-efficacy was measured using the Spanish adaptation of the
General Self-Efficacy Scale76. Sample size with pre-treatment assessment
on the Social Functioning Scale, the Anticipatory and Consummatory
Interpersonal Pleasure Scale-Adult version, and the General Self-Efficacy
Scale was smaller (n= 42 for the REHACOP group and n= 24 for the active
control group).
Regarding clinical symptoms, the Positive and Negative Syndrome
Scale77 was employed to measure positive symptoms, disorganization,
excitement, and depression, according to the five-factor solution proposed
by Wallwork et al.78. As recommended by the NIMH-MATRICS Consensus
Statement on Negative Symptoms79,80, primary negative symptoms were
assessed using the Brief Negative Symptom Scale81.
Satisfaction with the received treatment was assessed through the
Spanish adaptation of the Consumer Reports Effectiveness Scale82.
Premorbid IQ was measured by the Word Accentuation Test83, a Spanish
version of the National Adult Reading Test84. Premorbid IQ was estimated
using raw scores that were converted using the full-scale IQ of Gomar
et al.85.
Handedness was assessed by means of the Edinburgh Handedness
Inventory86. The following formula was used to estimate handedness
consistency: right−left/right+left.
Intervention
REHACOP is a group-based integrative cognitive remediation program that
combines training in neurocognition, social cognition, social skills, and
functional skills87. It integrates top–down and bottom–up strategies and
includes paper-and-pencil tasks, active group discussions, and role-playing.
REHACOP is highly structured, which minimizes the effect of being
administered by different therapists. This intervention program includes up
to 300 different tasks that are divided into different units and subtypes of
abilities. Tasks within each unit are hierarchically ordered according to a
subtype of abilities and levels of complexity to ensure a gradual increase in
cognitive demand (further explanation about REHACOP is provided
elsewhere35).
In this study, sessions were arranged for nine groups of between four
and eight patients each, at various centers which formed part of the
Mental Health Network in Álava (the Psychiatric Hospital of Álava, the
Association of Relative and Patients with Mental Illness from Ayala, and the
Community Rehabilitation Service Center). The clinical team who
conducted the intervention was trained in administering REHACOP and
used the same materials and instructions in all the groups, with the 60-
minute sessions being held 3 days a week over 20 weeks. The REHACOP
intervention group trained the following units: Attention unit (4 weeks),
with training in selective, sustained, alternating, and divided attention;
Learning and Memory unit (4 weeks), including visual and verbal learning,
recall, recognition memory, WM, and compensatory strategies; Language
unit (3 weeks) focused on syntax, vocabulary, grammar, verbal compre-
hension, verbal fluency, and abstract language; Executive Functions unit
(3 weeks), including cognitive and objective planning, novel problem
solving, CF, reasoning, categorization, and conceptualization; Social
Cognition unit (3 weeks), with training in EP, social reasoning, moral
dilemmas, and ToM; Social Skills unit (2 weeks); and Functional Skills unit
(1 week), including activities involved in daily living. In addition, several
tasks were timed to train PS throughout the first four units.
The active control group carried out occupational group activities
(gardening, sewing, handicrafts, painting, and music) with the same
duration and frequency as the REHACOP group. In addition, as part of the
standard treatment, patients from both the experimental and active
control groups received psychoeducation sessions.
If a patient missed one or more sessions for various reasons (e.g.,
vacation or leave), they received individual training in the contents that
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had been trained in the group session or alternatively, received feedback
through homework afterward. This allowed the patient to meet the
objectives of all the training sessions missed. The patient then rejoined the
experimental group. Therefore, patients made up all the missed sessions.
Moreover, the maximum number of sessions missed permitted was six
(2 weeks). Patients who stopped attending sessions and did not return
were considered dropouts (please see Fig. 1). Owing to the COVID-19
pandemic, several experimental (n= 13) and active control (n= 2) groups
were temporarily discontinued at the beginning of the interventions.
Therefore, individual booster sessions were conducted for 2 weeks before
intervention groups were resumed.
Data analyses
IBM SPSS version 26.0 (SPSS Inc., Chicago, USA) was used for statistical
analyses. Statistical analyses were carried out according to the ITT principle
(N= 94). In addition, per-protocol analyses were also performed (Supple-
mentary Tables 1–4) only with those participants who had completed the
post-treatment assessment (N= 81). The expectation-maximization algo-
rithm was used to impute missing values. The Little’s Missing Completely
at Random test showed that the missing data were missing completely at
random (X2 [6412]= 2800.45, p= 1.000). The Shapiro–Wilk test was used to
test data for normality. Differences between groups in terms of
sociodemographic, cognitive, creative, functional outcome, and clinical
variables at baseline were assessed by a two-tailed independent t test or
Mann–Whitney U test. Differences between groups in categorical data
were analyzed using the Chi-squared (X2) test.
An analysis of covariance was used to analyze the effectiveness of the
cognitive remediation, with baseline scores being entered as covariates.
Specifically, analysis of covariance was applied to compare change scores
(post-treatment−baseline) between the REHACOP group and the active
control group on each of the cognitive, creative, functional outcome, and
clinical variables, controlling baseline scores. A bootstrapping procedure88
was performed (1000 samples) to obtain adjusted mean differences in
change scores, using the Bonferroni adjustment. Effect sizes were calculated
using partial eta squared (η2p) and this was considered small (0.01), medium
(0.06), or large (0.14)0.89 The significance level was set at 0.05, and all tests
were two-tailed.
In order to analyze predictors of functional outcome, Spearman’s Rho
and Pearson’s r correlation analyses were first carried out between those
neurocognitive, social cognitive, creative, and clinical change variables and
functional outcome variables that had shown improvement after the
intervention. LISREL 9.290 was then used to perform a path analysis which
was conducted to assess the mediating role of these change scores in the
relationship between receiving integrative cognitive remediation (vs active
control group) and improvement in functional outcome. The robust
maximum likelihood method was used, which requires an estimate of the
asymptotic covariance matrix of the variances and covariates of the
sample, including the scaled χ2 Satorra-Bentler index (SB χ2). The CFI, NNFI,
and SRMR were used to evaluate the goodness of fit of the model.
According to Hu and Bentler (1999), CFI and NNFI values higher than 0.90
and SRMR values smaller than 0.08 indicate a good fit91.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The data that support the findings of this study are available from the corresponding
author on reasonable request. The data are not publicly available due to them
containing information that could compromise research participant privacy or
consent.
Received: 20 May 2021; Accepted: 1 October 2021;
REFERENCES
1. Vos, T. et al. Global, regional, and national incidence, prevalence, and years lived
with disability for 328 diseases and injuries for 195 countries, 1990-2016: a
systematic analysis for the Global Burden of Disease Study 2016. Lancet 390,
1211–1259 (2017).
2. Conus, P., Cotton, S., Schimmelmann, B. G., McGorry, P. D. & Lambert, M. The first-
episode psychosis outcome study: premorbid and baseline characteristics of an
epidemiological cohort of 661 first-episode psychosis patients. Early Interv. Psy-
chiatry 1, 191–200 (2007).
3. Harvey, P. D. Disability in schizophrenia: contributing factors and validated
assessments. J. Clin. Psychiatry 75, 15–20 (2014).
4. Fleischhacker, W. W. et al. Schizophrenia-Time to commit to policy change.
Schizophr. Bull. 40, S165–94 (2014).
5. Green, M. F., Horan, W. P. & Lee, J. Nonsocial and social cognition in schizophrenia:
current evidence and future directions. World Psychiatry 18, 146–161 (2019).
6. Galderisi, S. et al. The influence of illness-related variables, personal resources and
context-related factors on real-life functioning of people with schizophrenia.
World Psychiatry 13, 275–287 (2014).
7. Bowie, C. R. et al. Predicting schizophrenia patients’ real-world behavior with
specific neuropsychological and functional capacity measures. Biol. Psychiatry 63,
505–511 (2008).
8. Green, M. F. Impact of cognitive and social cognitive impairment on functional
outcomes in patients with schizophrenia. J. Clin. Psychiatry 77, 8–11 (2016).
9. Sampedro, A. et al. The impact of creativity on functional outcome in schizo-
phrenia: a mediational model. npj Schizophr. 7, 1–8 (2021).
10. Strassnig, M. T. et al. Determinants of different aspects of everyday outcome in
schizophrenia: the roles of negative symptoms, cognition, and functional capa-
city. Schizophr. Res. 165, 76–82 (2015).
11. Ojeda, N. et al. An outcome prediction model for schizophrenia: a structural
equation modelling approach. Rev. Psiquiatr. Salud Ment. 12, 232–241 (2019).
12. Galderisi, S. G. et al. The influence of illness-related variables, personal resources
and context-related factors on real-life functioning of people with schizophrenia.
World Psychiatry 13, 275–287 (2014).
13. Fervaha, G., Foussias, G., Agid, O. & Remington, G. Impact of primary negative
symptoms on functional outcomes in schizophrenia. Eur. Psychiatry 29, 449–455
(2014).
14. Fu, S., Czajkowski, N., Rund, B. R. & Torgalsbøen, A. K. The relationship between
level of cognitive impairments and functional outcome trajectories in first-
episode schizophrenia. Schizophr. Res. 190, 144–149 (2017).
15. Peña, J. et al. Mechanisms of functional improvement through cognitive reha-
bilitation in schizophrenia. J. Psychiatr. Res. 101, 21–27 (2018).
16. Green, M. F., Kern, R. S., Braff, D. L. & Mintz, J. Neurocognitive deficits and func-
tional outcome in schizophrenia: are we measuring the ‘right stuff’? Schizophr.
Bull. 26, 119–136 (2000).
17. Nemoto, T., Kashima, H. & Mizuno, M. Contribution of divergent thinking to
community functioning in schizophrenia. Prog. Neuro-Psychopharmacol. Biol.
Psychiatry 31, 517–524 (2007).
18. Nemoto, T. et al. Cognitive training for divergent thinking in schizophrenia: a pilot
study. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 1533–1536 (2009).
19. McGurk, S. R., Twamley, E. W., Sitzer, D. I., McHugo, G. J. & Mueser, K. T. A meta-
analysis of cognitive remediation in schizophrenia. Am. J. Psychiatry 164,
1791–1802 (2007).
20. Wykes, T., Huddy, V., Cellard, C., McGurk, S. R. & Czobor, P. A meta-analysis of
cognitive remediation for schizophrenia: Methodology and effect sizes. Am. J.
Psychiatry 168, 472–485 (2011).
21. Revell, E. R., Neill, J. C., Harte, M., Khan, Z. & Drake, R. J. A systematic review and
meta-analysis of cognitive remediation in early schizophrenia. Schizophr. Res 168,
213–22 (2015).
22. Cella, M. et al. Cognitive remediation for inpatients with psychosis: a systematic
review and meta-analysis. Psychol. Med. 50, 1062–1076 (2020).
23. Cella, M., Preti, A., Edwards, C., Dow, T. & Wykes, T. Cognitive remediation for
negative symptoms of schizophrenia: a network meta-analysis. Clin. Psychol. Rev.
52, 43–51 (2017).
24. Cella, M., Reeder, C. & Wykes, T. Cognitive remediation in schizophrenia — now it
is really getting personal. Curr. Opin. Behav. Sci. 4, 147–151 (2015).
25. Mueller, D. R., Schmidt, S. J. & Roder, V. One-year randomized controlled trial and
follow-up of integrated neurocognitive therapy for schizophrenia outpatients.
Schizophr. Bull. 41, 604–616 (2015).
26. Lindenmayer, J. P. et al. Does social cognition training augment response to
computer-assisted cognitive remediation for schizophrenia? Schizophr. Res. 201,
180–186 (2018).
27. Bechi, M. et al. Combined social cognitive and neurocognitive rehabilitation
strategies in schizophrenia: neuropsychological and psychopathological influ-
ences on Theory of Mind improvement. Psychol. Med. 45, 3147–3157 (2015).
28. Fisher, M. et al. Supplementing intensive targeted computerized cognitive
training with social cognitive exercises for people with schizophrenia: an interim
report. Psychiatr. Rehabil. J. 40, 21–32 (2017).
A. Sampedro et al.
9
Published in partnership with the Schizophrenia International Research Society npj Schizophrenia (2021)    52 
29. Fernandez-Gonzalo, S. et al. A new computerized cognitive and social cognition
training specifically designed for patients with schizophrenia/schizoaffective
disorder in early stages of illness: a pilot study. Psychiatry Res. 228, 501–509
(2015).
30. Hooker, C. I. et al. Neural activity during emotion recognition after combined
cognitive plus social-cognitive training in schizophrenia. Schizophr. Res 139,
53–59 (2012).
31. Eack, S. M. et al. Cognitive enhancement therapy for early course schizophrenia:
effects of a two-year randomized controlled trial. Psychiatr. Serv. 60, 1468–1476
(2009).
32. Galderisi, S. et al. Social skills and neurocognitive individualized training in
schizophrenia: comparison with structured leisure activities. Eur. Arch. Psychiatry
Clin. Neurosci. 260, 305–315 (2010).
33. Bell, M., Zito, W., Greig, T. & Wexler, B. E. Neurocognitive enhancement therapy
and competitive employment in schizophrenia: Effects on clients with poor
community functioning. Am. J. Psychiatr. Rehabil. 11, 109–122 (2008).
34. Bowie, C. R., Mcgurk, S. R., Mausbach, B., Patterson, T. L. & Harvey, P. D. Combined
cognitive remediation and functional skills training for schizophrenia: effects on
cognition, functional competence, and real-world behavior. Am. J. Psychiatry 169,
710–718 (2012).
35. Sánchez, P. et al. Improvements in negative symptoms and functional outcome
after a new generation cognitive remediation program: a randomized controlled
trial. Schizophr. Bull. 40, 707–715 (2014).
36. Peña, J. et al. Combining social cognitive treatment, cognitive remediation, and
functional skills training in schizophrenia: a randomized controlled trial. npj
Schizophr. 2, 16037 (2016).
37. Granholm, E., Holden, J., Link, P. C. & Mcquaid, J. R. Randomized clinical trial of
cognitive behavioral social skills training for schizophrenia: improvement in
functioning and experiential negative symptoms. J. Consult. Clin. Psychol. 82,
1173–1185 (2014).
38. Sampedro, A. et al. Mediating role of cognition and social cognition on creativity
among patients with schizophrenia and healthy controls: revisiting the shared
vulnerability model. Psychiatry Clin. Neurosci. 74, 1–7 (2019).
39. Sampedro, A. et al. Neurocognitive, social cognitive, and clinical predictors of
creativity in schizophrenia. J. Psychiatr. Res. 129, 206–213 (2020).
40. Abraham, A., Windmann, S., McKenna, P. & Güntürkün, O. Creative thinking in
schizophrenia: the role of executive dysfunction and symptom severity. Cogn.
Neuropsychiatry 12, 235–258 (2007).
41. Jaracz, J., Patrzała, A. & Rybakowski, J. K. Creative thinking deficits in patients with
schizophrenia: neurocognitive correlates. J. Nerv. Ment. Dis. 200, 588–593 (2012).
42. Kiritsis, P. Preserving the creative advantages of schizophrenia: a quantitative
pretest-posttest study on the effects of cognitive remediation training on crea-
tivity. (Sofia University, 2018).
43. Barlati, S. et al. Factors associated with response and resistance to cognitive
remediation in schizophrenia: a critical review. Front. Pharmacol. 9, 1–11 (2019).
44. Seccomandi, B., Tsapekos, D., Newbery, K., Wykes, T. & Cella, M. A systematic
review of moderators of cognitive remediation response for people with schi-
zophrenia. Schizophr. Res. Cogn 19, 10060 (2020).
45. Wykes, T. et al. Developing models of how cognitive improvements change
functioning: mediation, moderation and moderated mediation. Schizophr. Res.
138, 88–93 (2012).
46. Eack, S. M., Geile, M. F. P., Greenwald, D. P., Hogarty, S. S. & Keshavan, M. S.
Mechanisms of functional improvement in a 2 year trial of cognitive enhance-
ment therapy for early schizophrenia Mechanisms of functional improvement in
a 2-year trial of cognitive enhancement therapy for early schizophrenia. Psychol.
Med. 41, 1253–1261 (2011).
47. Rispaud, S. G., Rose, J. & Kurtz, M. M. The relationship between change in cog-
nition and change in functional ability in schizophrenia during cognitive and
psychosocial rehabilitation. Psychiatry Res. 244, 145–150 (2016).
48. Fiszdon, J. M., Choi, J., Goulet, J. & Bell, M. D. Temporal relationship between
change in cognition and change in functioning in schizophrenia. Schizophr. Res.
105, 105–113 (2008).
49. Seccomandi, B. et al. Can IQ moderate the response to cognitive remediation in
people with schizophrenia? J. Psychiatr. Res. 133, 38–45 (2021).
50. Seccomandi, B. et al. Exploring the role of age as a moderator of cognitive
remediation for people with schizophrenia. Schizophr. Res. 228, 29–35 (2021).
51. Kurtz, M. M., Wexler, B. E., Fujimoto, M., Shagan, D. S. & Seltzer, J. C. Symptoms
versus neurocognition as predictors of change in life skills in schizophrenia after
outpatient rehabilitation. Schizophr. Res. 102, 303–311 (2008).
52. Twamley, E. W., Burton, C. Z. & Vella, L. Compensatory cognitive training for
psychosis: who benefits? who stays in treatment? Schizophr. Bull. 37, 55–62
(2011).
53. Wykes, T. et al. Cognitive remediation therapy (CRT) for young early onset
patients with schizophrenia: an exploratory randomized controlled trial. Schi-
zophr. Res. 94, 221–230 (2007).
54. Twamley, E. W., Savla, G. N., Zurhellen, C. H., Heaton, R. K. & Jeste, V. Cognitive
training intervention for people with psychosis. Am. J. Psychiatr. Rehabil. 11,
144–163 (2009).
55. Kurtz, M. M., Gagen, E., Rocha, N. B. F., Machado, S. & Penn, D. L. Comprehensive
treatments for social cognitive deficits in schizophrenia: A critical review and
effect-size analysis of controlled studies. Clin. Psychol. Rev. 43, 80–89 (2016).
56. Ahmed, A. O. et al. A randomized study of cognitive remediation for forensic and
mental health patients with schizophrenia. J. Psychiatr. Res. 68, 8–18 (2015).
57. Kalinowska, S. et al. The association between lifestyle choices and schizophrenia
symptoms. J. Clin. Med. 10, 165 (2021).
58. Farreny, A. et al. Baseline predictors for success following strategy-based cognitive
remediation group training in schizophrenia. J. Nerv. Ment. Dis. 204, 585–589 (2016).
59. Bell, M. D., Choi, K. H., Dyer, C. & Wexler, B. E. Benefits of cognitive remediation
and supported employment for schizophrenia patients with poor community
functioning. Psychiatr. Serv. 65, 469–475 (2014).
60. Cai, C., Yu, L., Rong, L. & Zhong, H. Effectiveness of humor intervention for
patients with schizophrenia: a randomized controlled trial. J. Psychiatr. Res. 59,
174–178 (2014).
61. American Psychiatric Association. Diagnostic and Statistical Manual of Mental
Disorders. (American Psychiatric Association, 2013).
62. Csernansky, J. G., Mahmoud, R. & Brenner, R. A comparison of risperidone and
haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J.
Med. 346, 16–22 (2002).
63. Faul, F., Erdfeldel, E., Lang, A.-G. & Buchner, A. G*Power 3: a flexible statistical
power analysis program for the social, behavioral, and biomedical. Behav. Res.
Methods 39, 175–191 (2007).
64. Schretlen, D. Modified Wisconsin Card Sorting Test professional manual. (PAR,
2010).
65. Wechsler, D. WAIS-III Manual: Wechsler Adult Intelligence Scale-III. (Psychological
Corporation, 1997).
66. Golden, C. J. STROOP: Test de colores y palabras. (2010).
67. Brandt, J. & Benedict, R. Hopkins Verbal Learning Test– Revised. (Psychological
Assessment Resources, 2001).
68. Happé, F. G. An advanced test of theory of mind: understanding of story char-
acters’ thoughts and feelings by able autistic, mentally handicapped, and normal
children and adults. J. Autism Dev. Disord. 24, 129–154 (1994).
69. Johannesen, J. K., Lurie, J. B., Fiszdon, J. M. & Bell, M. D. The social attribution task-
multiple choice (SAT-MC): a psychometric and equivalence study of an alternate
form. ISRN Psychiatry 2013, 1–9 (2013).
70. Bell, M., Bryson, G. & Lysaker, P. Positive and negative affect recognition in
schizophrenia: a comparison with substance abuse and normal control subjects.
Psychiatry Res. 73, 73–82 (1997).
71. Torrance, E. P. The Torrance Tests of Creative Thinking — Norms-Technical Manual
Research Edition—Verbal Tests, Forms A and B— Figural tests, Forms A and B.
(Personnel Press, 1966).
72. Torrance, E. P. Torrance Tests of Creative Thinking. (Scholastic Testing Service. Inc.,
2016).
73. Garcia-Portilla, M. P. et al. Validation of a European Spanish-version of the Uni-
versity of California performance Skills Assessment (Sp-UPSA) in patients with
schizophrenia and bipolar disorder. Schizophr. Res. 150, 421–426 (2013).
74. Alonso, J. et al. Desarrollo y validación de la versión corta de la Escala de Fun-
cionamiento Social en esquizofrenia para su uso en la práctica clínica. Actas Esp.
Psiquiatr. 36, 102–110 (2008).
75. Gooding, D. C., Fonseca-Pedrero, E., Pérez De Albéniz, A., Ortuño-Sierra, J. &
Paino, M. Adaptación española de la versión para adultos de la Escala de Placer
Interpersonal Anticipatorio y Consumatorio. Rev. Psiquiatr. Salud Ment. 9, 70–77
(2016).
76. Sanjuán Suárez, P., Pérez García, A. M. & Bermúdez Moreno, J. Escala de auto-
eficacia general: Datos psicométricos de la adaptación para población española.
Psicothema 12, 509–513 (2000).
77. Kay, S. R., Fiszbein, A. & Opler, L. A. The positive and negative syndrome scale
(PANSS) for schizophrenia. Schizophr. Bull. 13, 261–276 (1987).
78. Wallwork, R. S., Fortgang, R., Hashimoto, R., Weinberger, D. R. & Dickinson, D.
Searching for a consensus five-factor model of the Positive and Negative Syn-
drome Scale for schizophrenia. Schizophr. Res. 137, 246–250 (2012).
79. Carpenter, W. T., Blanchard, J. J. & Kirkpatrick, B. New standards for negative
symptom assessment. Schizophr. Bull. 42, 1–3 (2016).
80. Kirkpatrick, B., Fenton, W. S., Carpenter, W. T. & Marder, S. R. The NIMH-MATRICS
consensus statement on negative symptoms. Schizophr. Bull 32, 214–219 (2006).
81. Kirkpatrick, B. et al. The brief negative symptom scale: psychometric properties.
Schizophr. Bull. 37, 300–305 (2011).
82. Feixas, G. et al. Escala de satisfacción con el tratamiento recibido (CRES-4): la
versión en español. Rev. Psicoter. 23, 51–58 (2012).
83. Del Ser, T., Gonzalez-Montalvo, J. I., Martinez-Espinosa, S., Delgado-Villapalos, C. &
Bermejo, F. Estimation of premorbid intelligence in Spanish people with the word
A. Sampedro et al.
10
npj Schizophrenia (2021)    52 Published in partnership with the Schizophrenia International Research Society
accentuation test and its application to the diagnosis of dementia. Brain Cogn.
33, 343–356 (1997).
84. Nelson, H. E. & Willison, J. National Adult Reading Test (NART). (1991).
85. Gomar, J. J. et al. Validation of the Word Accentuation Test (TAP) as a means of
estimating premorbid IQ in Spanish speakers. Schizophr. Res. 128, 175–176 (2011).
86. Oldfield, R. C. The assessment of handedness: the Edinburgh inventory. Neu-
ropsychologia 9, 97–113 (1971).
87. Ojeda, N. & Peña, J. REHACOP: programa de rehabilitación neuropsicológica en
psicosis. (Parima Digital, 2012).
88. Efron, B. & Tibshirani, R. An Introduction to the Bootstrap. (Chapman & Hall, 1993).
89. Cohen, J.Statistical Power Analysis for the Behavioral Sciences. (1988).
90. Jöreskog, K. & Sörbom, D. LISREL 9.20 for Windows [Computer software]. (2015).
91. Hu, L. T. & Bentler, P. M. Cutoff criteria for fit indexes in covariance structure
analysis: conventional criteria versus new alternatives. Struct. Equ. Model. 6, 1–55
(1999).
ACKNOWLEDGEMENTS
This work was supported by the Carlos III Health Institute of the Spanish Ministry of
Economy and Competitiveness (PI16/01022); the Department of Education and
Science of the Basque Government (Team A) (IT946‐16); the Fundación Tatiana Pérez
de Guzmán el Bueno (to AS); and the University of the Basque Country (UPV/EHU)
(PIF 19/40 to MTE). The funding agencies had no role in the design, data collection,
and analysis, decision to publish, or preparation of the study. The authors thank all
the participants and clinical teams who were involved in this study as well as the
English language editing service. Our special thanks to Amaia Ortiz de Zarate, Edorta
Elizagárate, and Isabel Hervella for all the support in the recruitment and
management of patients.
AUTHOR CONTRIBUTIONS
N.O., N.I.B., J.P., and P.S. designed the study and wrote the protocol. A.S., P.S., N.I.Y.,
A.G.G., M.T.E., and C.P. performed the clinical and neuropsychological evaluations. A.S.
and J.P. managed the literature searches and undertook the statistical analysis. A.S.
and J.P. wrote the first draft of the manuscript. All authors contributed to the writing
and revision of the manuscript. All authors have approved the final manuscript.
COMPETING INTERESTS
N.O. and J.P. are co-authors and copyright holders of the REHACOP program of
cognitive remediation, published by Parima Digital, SL (Bilbao, Spain).
ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41537-021-00181-0.
Correspondence and requests for materials should be addressed to Javier Peña.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2021
A. Sampedro et al.
11
Published in partnership with the Schizophrenia International Research Society npj Schizophrenia (2021)    52 
